濮阳东方看妇科很不错濮阳东方医院治阳痿价格比较低,濮阳东方医院割包皮手术安全不,濮阳东方男科医院割包皮手术比较专业,濮阳东方男科医院割包皮手术收费标准,濮阳东方男科坐公交路线,濮阳东方医院看阳痿价格不贵,濮阳东方医院看男科病技术可靠

WASHINGTON, April 4 (Xinhua) -- New research from the University of Pennsylvania School of Medicine has revealed an increased incidence of major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death, in patients with severe psoriasis. The study results were reported Monday at the annual American College of Cardiology meeting in New Orleans.Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular disease. However, the degree to which psoriasis is associated with MACE has not been defined.In a cohort study analyzing data from a general practice research database, Lead author Nehal Mehta, director of Inflammatory Risk in Penn's Preventive Cardiology program, and colleagues reviewed the case histories of over 3,600 patients with severe psoriasis and 14,300 controls. They found that patients with severe psoriasis have a 53 percent increased incidence of MACE compared to the general population. They also found that having a diagnosed case of severe psoriasis confers an additional ten-year risk of six percent on MACE.Previous work from Mehta and colleagues found that the risk of death from cardiovascular disease increased by 57 percent in patients with severe psoriasis. In addition, the relative risk of death from cardiovascular disease was even higher in younger patients, who were as young as age 40.The researchers conclude that this new estimate of increased ten-year MACE may warrant more aggressive strategies for treatment of cardiovascular risk factors in patients with psoriasis.

WELLINGTON, May 22 (Xinhua) -- One in every eight women giving birth in a New Zealand hospital last year was Asian, local media reported Sunday.In the country's most populous city, Auckland, 5,149 Asian women gave birth, more than double the number of 15 years ago, the New Zealand Herald reported.Last year was the first year in the city when more Asian women gave birth than indigenous Maori women, who registered 5,015 births.Citing figures from the government statistics agency, Statistics New Zealand, the report said the majority of women nationwide who gave birth last year were still of European descent, accounting for 43,965 of last year's 63,897 births.But more women of other ethnic backgrounds were also becoming mothers, including those from the Middle East, Latin America and Africa.Auckland University head of obstetrics and gynaecology, Professor Lesley McCowan, said the increase reflected New Zealand is an increasingly multicultural society.

ADDIS ABABA, Jan. 28 (Xinhua) -- Fruitful results have been achieved some one year after the fourth ministerial meeting of the Forum on China-Africa Cooperation (FOCAC), Chinese envoy and Assistant Foreign Minister Liu Zhenmin told Xinhua here on Friday.Liu was in the Ethiopian capital Addis Ababa to attend the 16th African Union (AU) summit as special envoy of the Chinese government.During the FOCAC ministerial meeting held in November 2009 in Sharm el-Sheikh, Egypt, the Chinese government announced eight new measures of promoting Sino-African cooperation.Since then, China has been actively implementing various programs and projects according to the eight new measures, Liu said.The “China-Africa Science and Technology Partnership Program” and the “China-Africa Joint Research and Exchange Program” have been launched, Liu said, adding that the aid program of agricultural demonstration center is in smooth implementation process.Meanwhile, China is actively working on establishing the China-Africa partnership in addressing climate change, and is strengthening communication and coordination with Africa on the issue of climate change, Liu said.The Chinese envoy added that various programs and events such as the China-Africa Agricultural Cooperation Forum, the “African Culture in Focus 2010” activities, and the “20+20 Cooperation Plan of Chinese and African Institutions of Higher Learning” have been launched or successfully held. He said these events have promoted the comprehensive development of China-Africa relations.A wide range of other measures are also being carried out in an active manner, according to Liu.The year 2011 is key to the implementation of the measures announced on the fourth ministerial meeting of FOCAC, Liu stressed.To this end, China will continue strengthening communication and coordination with African countries, carrying out close cooperation and pushing forward the development of the China-Africa new strategic partnership, he pledged.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.